Chronic GVHD is a significant complication following allogeneic hematopoietic stem cell transplantation; however, the clinical characteristics of chronic GVHD following cord blood transplantation (CBT) in adults have not been well described. Between March 2001 and November 2005, a total of 77 patients underwent CBT at eight transplantation centers of the Nagoya Blood and Marrow Transplantation Group. Of 77 patients, 29 survived without graft failure or progression of underlying diseases for at least 100 days after transplantation. The median age of the 29 patients was 42 years (range, 18-67 years). Seven patients developed chronic GVHD (extensive, n ¼ 4; limited, n ¼ 3) disease. The cumulative incidence of chronic GVHD 1 year after day 100 was 24% (95% confidence interval (CI), 11-41%), and the organs involved were the skin (n ¼ 6), oral cavity (n ¼ 4), liver (n ¼ 1) and gastrointestinal tract (n ¼ 1). In three patients, chronic GVHD was resolved with supportive care. The remaining four were successfully treated with additional immunosuppressive therapy. Event-free survival rates of the 29 patients with and without chronic GVHD 3 years after day 100 were 83 (95% CI, 27-97%) and 36% (95% CI, 17-56%), respectively (P ¼ 0.047). These results suggest that chronic GVHD following CBT is mild and has a graft-versus-malignancy effect.
Introduction
Chronic GVHD is a major cause of morbidity and mortality in recipients who survive longer than 100 days after allogeneic BMT and peripheral blood stem cell transplantation (PBSCT). The clinical manifestations of chronic GVHD resemble those of autoimmune diseases; chronic GVHD occasionally involves multiple organs and can impair the quality of life of transplant recipients. [1] [2] [3] [4] Cord blood transplantation (CBT) is an attractive alternative for patients with advanced hematological malignancy who lack matched related or unrelated donors. Adult patients receiving myeloablative or reduced-intensity CBT have a 90% chance of engraftment, but also experience a 50% rate of transplant-related mortality, which is primarily attributable to infection. [5] [6] [7] [8] [9] [10] The clinical characteristics of patients with chronic GVHD after CBT have not been well described. Studies dealing with CBT have mainly focused on short-term events, such as engraftment, acute GVHD, infections and regimen-related toxicities. Several groups have reported chronic GVHD rates from 17 to 89%. However, studies dealing with the details of the clinical characteristics of chronic GVHD, including the target organs, grading and treatment response, are limited. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Although we recently reported the clinical characteristics of early immune reactions following CBT, those of chronic immune reactions remain unknown. 21 Given that chronic GVHD is a major complication for long-term survivors, the clinical characteristics of CBT patients with chronic GVHD need to be investigated to improve these patients' outcomes. In the present study, we assessed the clinical characteristics of chronic GVHD following CBT which were conducted in eight centers of the Nagoya Blood and Marrow Transplantation Group (NBMTG), using the grading systems proposed by Akpek et al. 22, 23 and the National Institutes of Health (NIH) consensus development project, 24 which are new grading systems in BMT and PBSCT patients. 25, 26 Patients and methods
Study patients
Between March 2001 and November 2005, a total of 77 patients underwent CBT at eight centers of NBMTG. The transplantation procedures have been previously described. 21 Purine analog-based regimens were defined as reduced-intensity preparative regimens. All patients presented with hematological disorders that were incurable using conventional treatments and were considered unsuitable for conventional allo-SCT due to a lack of HLA-identical siblings or suitable unrelated donor. Patients450 years old and/or with organ dysfunction received reduced-intensity CBT. Acute leukemia in complete remission, chronic myelogenous leukemia in the chronic phase, malignant lymphoma in complete remission, multiple myeloma in complete remission and aplastic anemia were defined as low risk, while all other conditions were considered high risk. All patients provided written informed consent prior to CBT.
Diagnosis and management of acute and chronic GVHD
Patients with acute and chronic GVHD were assigned a grade according to established criteria. 27, 28 Patients with chronic GVHD were also assigned a grade according to the criteria proposed by Akpek et al., 22, 23 which include extent of skin involvement, platelet count and progressive-type onset. The scoring for the criteria is as follows: (1) if the extent of skin involvement is more than 50% of body surface area, allocate 1, otherwise 0; (2) if the platelet count is less than 100 Â 10 9 /l, allocate 1, otherwise 0 and (3) if the chronic GVHD is progressive-type onset, allocate 1, otherwise 0. The patients were categorized into three grades: grade I (0 risk factors), grade II (1 risk factor or thrombocytopenia þ progressive-type onset) and grade III (2-3 risk factors). If the presentation of chronic GVHD was progressive, the date of onset was defined as day 100. Chronic GVHD was also graded according to the criteria proposed by the NIH consensus development project. 24 GVHD prophylaxis involved continuous infusion of cyclosporine 3 mg/kg or tacrolimus 0.03 mg/kg from day À1 until the patient tolerated oral administration with or without short-term MTX ( Table 1 ). The dosage and the schedule of the short-term MTX therapy are shown in Table 1 . Patients with grade II-IV acute GVHD were given 0.5-2.0 mg/kg per day of prednisolone or methylprednisolone. Patients with the extensive type of chronic GVHD received corticosteroid treatment; the corticosteroid dose was left to the physicians' discretion.
Definitions
Neutrophil engraftment was defined as an absolute neutrophil count X0.5 Â 10 9 /l for 3 consecutive days. Graft failure was defined as previously described:
29 the combination of peripheral cytopenia and marrow hypoplasia for 460 days of CBT with the existence of donor-type hematopoiesis (mixed or complete donor chimerism) or complete loss of donor-type hematopoiesis occurring anytime after transplantation. Peripheral cytopenia was defined as an absolute neutrophil count o0.5 Â 10 9 /l and a platelet count o20 Â 10 9 /l. Relapse or progression of underlying disease was evaluated hematologically. Nonrelapse mortality was defined as any death without progression of the underlying disease.
Immune reactions were defined as previously described. 30 When febrile patients (body temperature X38 1C) with no evidence of infection or medication-related adverse effects exhibited skin eruption, diarrhea, jaundice (serum total bilirubin42.0 mg/dl) or body weight gain410% of baseline, these changes were defined as immune reactions.
Based on their timing, reactions were classified into three subtypes: pre-, peri-and post-engraftment. Immune reactions developing X6 days before engraftment were defined as pre-engraftment immune reaction (PIR), while reactions occurring within 5 days of engraftment were defined as engraftment syndrome (ES). Other reactions were defined as post-ES, generally corresponding to acute GVHD. The responses to corticosteroid treatment of PIR, ES and acute GVHD were evaluated according to previously published criteria. 31 Death, graft failure and progression of underlying disease were defined as events. Event-free survival was calculated from the day of transplantation to the onset of an event. Overall survival was calculated from the day of transplantation to death. Karnofsky performance status was defined as previously described. 32 End points and statistical analysis The primary aim of this study was to investigate the clinical characteristics of chronic GVHD following CBT. The secondary aim was to investigate the clinical impact of chronic GVHD on patient outcomes.
For all survival analyses, day 100 after CBT was defined as the initial date. The overall survival rate, the event-free survival rate and the relapse rate stratified by development of chronic GVHD were assessed using the Kaplan-Meier product-limit method, treating chronic GVHD as a timedependent covariate. Patients were included in the nonchronic GVHD group until the onset of chronic GVHD, at which time they were switched to the chronic GVHD group. The Wilcoxon test was used to compare the results. To eliminate the effect of competing risk, cumulative incidences of chronic GVHD and relapse were assessed using methods described elsewhere. 33, 34 In the cumulative incidence analyses, a competing event was defined as death without chronic GVHD and progression of underlying disease. Univariate Cox proportional hazards mode was used to assess the impact of potential risk factors for the development of chronic GVHD. Values of Po0.05 were considered statistically significant. All analyses were conducted using Stata version 10.0 software (Stata Corp., College Station, TX, USA).
Results

Characteristics of study patients
Of 77 patients, 29 survived without any event for at least 100 days after transplantation. Patient characteristics are shown in Table 1 . The patients received myeloablative Table 1 ). The median follow-up of surviving patients was 35.3 months (range, 4.2-70.5 months).
Incidence of chronic GVHD Of 29 patients, 7 developed chronic GVHD at a median of day 100 (range, day 100-360). The cumulative incidence of chronic GVHD 1 year after day 100 was 24% (95% confidence interval (CI), 11-41%; Figure 1 ). The cumulative incidence of extensive disease was 10% (95% CI, 3-25%).
Clinical features of chronic GVHD
The clinical features of chronic GVHD are shown in Table 2 ; four patients had extensive and three had limited disease. According to the grading proposed by Akpek et al., 22 two of these patients were categorized into grade I, and five were categorized into grade II. According to the grading proposed by the NIH consensus development project, six of these patients were categorized into mild, and one was categorized into moderate. The type of onset included quiescent onset (n ¼ 1), de novo onset (n ¼ 3) and progressive onset (n ¼ 3). The organs involved by chronic GVHD included the skin (n ¼ 6), oral cavity (n ¼ 4), liver (n ¼ 1) and gastrointestinal tract (n ¼ 1). In three patients, chronic GVHD resolved with supportive care, and the remaining four patients were successfully treated with prednisolone (n ¼ 2), cyclosporine plus prednisolone (n ¼ 1) and tacrolimus plus prednisolone (n ¼ 1). 200 300 400 500 600 Days after transplantation Figure 1 Cumulative incidence of chronic GVHD. The cumulative incidence of chronic GVHD 1 year after day 100 was 24% (95% CI, 11-41%).
Chronic GVHD following CBT K Sugimoto et al Table 2 Characteristics and outcomes of patients with chronic GVHD Liver function tests at onset of chronic GVHD were as follows; total serum bilirubin, 0.3 mg/dl; alanine aminotransferase, 65 U/l; alkaline phosphatase, 814 U/l (upper limits of normal, o359 U/l). The patient developed skin eruption as ES. It subsided spontaneously.
Risk factors for chronic GVHD
Risks factors for chronic GVHD are shown in Table 3 . On univariate analysis, no risk factors for chronic GVHD were identified.
Overall and event-free survival
Overall survival rates of the 29 patients at 1 and 3 years after day 100 were 69 (95% CI, 49-83%) and 53% (95% CI, 32-70%), respectively. A total of 13 patients died 100 days after transplantation. The primary causes of death included progression of primary diseases (n ¼ 5), infection (n ¼ 4), hepatic failure caused by acute GVHD (n ¼ 2), cerebral hemorrhage (n ¼ 1) and intestinal thrombotic microangiopathy (n ¼ 1). Sixteen patients were alive at last follow-up; the median Karnofsky performance status of these patients was 100% (range, 60-100%). The overall survival rates of patients with and without chronic GVHD 3 years after day 100 were 83 (95% CI, 27-97%) and 44% (95% CI, 22-64%), respectively (Wilcoxon test, P ¼ 0.076; Figure 2) .
The event-free survival rates of the 29 patients 1 and 3 years after day 100 were 56 (95% CI, 37-72%) and 47% (95% CI, 28-65%), respectively. Event-free survival rates of patients with and without chronic GVHD 3 years after day 100 were 83 (95% CI, 27-97%) and 36% (95% CI, 17-56%), respectively (Wilcoxon test, P ¼ 0.047; Figure 3) .
The cumulative incidences of relapse or progression of underlying disease in patients with and without chronic GVHD 3 years after day 100 were 14 (95% CI, 2-67%) and 32% (95% CI, 17-56%), respectively (Wilcoxon test, P ¼ 0.31).
Discussion
Several unique characteristics of patients with chronic GVHD after CBT were identified in the present study. First, the incidence of chronic GVHD after CBT (24%) was lower than after HLA-matched BMT in the Japanese patients (approximately 45%). 35, 36 In the present study, the extensive type accounted for 57% of chronic GVHD after CBT; the frequency was comparable with that after HLA-matched BMT. 35, 36 Second, chronic GVHD had a 100% favorable response rate to immunosuppressants and was not fatal. This is in sharp contrast to the chronic GVHD that develops in BMT or PBSCT, since 20-40% of chronic GVHD is fatal in such patients. 1, 2, 4, 32, [36] [37] [38] [39] [40] Third, chronic GVHD after CBT infrequently involves vital Figure 2 Overall survival rate. The overall survival rates of patients with and without chronic GVHD 3 years after day 100 were 83 (95% CI, 27-97%) and 44% (95% CI, 22-64%), respectively (Wilcoxon test, P ¼ 0.076).
Patients were included in the nonchronic GVHD group until the onset of chronic GVHD, at which time they were switched to the chronic GVHD group. with and without chronic GVHD 3 years after day 100 were 83% (95% CI, 27-97%) and 36% (95% CI, 17-56%), respectively (Wilcoxon test, P ¼ 0.047). Patients were included in the nonchronic GVHD group until the onset of chronic GVHD, at which time they were switched to the chronic GVHD group.
organs, such as the liver and the lung; instead, the skin and oral cavity are involved. Fourth, chronic GVHD after CBT does not impair transplant recipients' quality of life; all of the patients who developed chronic GVHD without disease progression maintained Karnofsky performance status of at least 90%. This is in contrast to chronic GVHD after BMT or PBSCT, which occasionally impairs quality of life. 36, 37 Lastly, all of the patients with chronic GVHD were classified as belonging to the favorable risk group according to the new grading systems. [22] [23] [24] Thus, these findings demonstrate that although chronic GVHD is a significant complication in CBT, its characteristics are different from those of GVHD following BMT and PBSCT; it is mild and infrequent. The clinical courses of chronic GVHD after CBT may be related to the immature lymphocytes in cord blood which are immunologically tolerant, 41, 42 while the basic mechanism has been unknown and awaits further investigations.
Chronic GVHD after CBT improved overall survival and event-free survival, which suggests that it has a graftversus-malignancy effect. In BMT and PBSCT patients, chronic GVHD has been reported to improve event-free survival, while its effects on overall survival were marginal. 28, 43, 44 These findings have been explained by the fact that chronic GVHD reduces the risk of progression of the underlying disease due to a graft-versus-malignancy effect, while it increases the risk of transplant-related mortalities. However, given the results of the present study in CBT patients, it is probable that chronic GVHD in CBT patients infrequently causes morbidity and mortality due to its mild characteristics and carries a graft-versus-malignancy effect. Future large-scale studies would allow a proper interpretation.
The risk factors for the development of chronic GVHD have still to be identified. In BMT or PBSCT, HLA match, prior onset of acute GVHD, age and infused cells were identified as risk factors of chronic GVHD. 35, 41, [45] [46] [47] Surprisingly, in the present study, these conventional risk factors for BMT or PBSCT were not found to be associated with chronic GVHD in CBT. While this may be due to differences in the basic mechanisms underlying GVHD after BMT/PBSCT and CBT, the present study may not have had sufficient statistical power to identify significant associations due to its small sample size. Further studies are warranted.
The present study identified novel information about the chronic GVHD that occurs after CBT; nevertheless, several issues still have to be resolved. First, limitations in our multicenter study included the small, retrospective nature and the various preparative regimens and GVHD prophylaxes in the patients; the unrecognized bias might have affected the results. Second, a new prognostic model that can be applied to CBT needs to be established. In the present study, most of the patients were classified as belonging to one group, the favorable risk group, according to the grading system proposed both by Akpek et al. and the NIH consensus development project; [22] [23] [24] thus, they may not be useful for classifying patients with chronic GVHD after CBT. Finally, patients with chronic GVHD were treated according to the strategy established for BMT. Given that the clinical characteristics of chronic GVHD differ between BMT/PBSCT and CBT, the optimal strategy for GVHD after CBT has yet to be established.
In conclusion, it was found that chronic GVHD after CBT is mild with a possible sparing graft-versus-malignancy effect. Since chronic GVHD is the most significant complication that affects morbidity and mortality of long-term survivors, a high quality of life can be expected in long-term CBT survivors. Once the high initial mortality within 100 days after CBT is improved, CBT will likely be considered a more promising transplantation method.
